Article info
PDFClinical ethics
A discussion on controversies and ethical dilemmas in prostate cancer screening
- Correspondence to Dr Satish Chandra Mishra, Department of Surgery, WHO Collaboration Centre for Research in Surgical Care Delivery in LMIC, Bhabha Atomic Research Centre Hospital, Mumbai, MH 400094, India; mishrasatishdr{at}gmail.com
Citation
A discussion on controversies and ethical dilemmas in prostate cancer screening
Publication history
- Received November 21, 2019
- Revised May 17, 2020
- Accepted May 22, 2020
- First published July 6, 2020.
Online issue publication
February 22, 2021
Article Versions
- Previous version (6 July 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Prostate cancer screening with prostate - specific antigen (PSA) test: a clinical practice guideline
- Prostate cancer screening with prostate - specific antigen (PSA) test: a systematic review and meta-analysis
- Prostate cancer screening and the management of clinically localized disease
- The impact of different prostate - specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false - positive biopsy recommendations: a population - based cohort study
- Knowledge and practice of prostate cancer screening among general practitioners in Malaysia: a cross-sectional study
- Screening for prostate cancer: time to put all the data on the table
- Young - age prostate cancer
- Prediction models for prostate cancer to be used in the primary care setting: a systematic review
- Guidelines for processing and reporting of prostatic needle biopsies
- Randomised prostate cancer screening trial: 20 year follow - up